Marshall Wace, LLP Sage Therapeutics, Inc. Call Options Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SAGE
# of Institutions
208Shares Held
42.6MCall Options Held
312KPut Options Held
294K-
Black Rock Inc. New York, NY5.22MShares$37.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$36.4 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$32.1 Million4.6% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.04MShares$14.6 Million0.57% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.62MShares$11.6 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $426M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...